Pulmonx (NASDAQ:LUNG) Price Target Cut to $5.00 by Analysts at Canaccord Genuity Group

Pulmonx (NASDAQ:LUNG) had its price objective lowered by research analysts at Canaccord Genuity Group from $6.00 to $5.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 210.56% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a research note on Thursday. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pulmonx currently has an average rating of “Hold” and a consensus target price of $5.38.

Pulmonx Price Performance

Shares of NASDAQ LUNG traded up $0.17 during midday trading on Thursday, reaching $1.61. The company’s stock had a trading volume of 1,749,305 shares, compared to its average volume of 395,841. The business’s 50 day moving average price is $1.77 and its two-hundred day moving average price is $1.79. Pulmonx has a fifty-two week low of $1.31 and a fifty-two week high of $8.12. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. The company has a market cap of $66.41 million, a P/E ratio of -1.14 and a beta of 0.07.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, March 4th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.14. The firm had revenue of $22.60 million during the quarter, compared to the consensus estimate of $21.73 million. Pulmonx had a negative return on equity of 77.58% and a negative net margin of 61.91%. On average, analysts forecast that Pulmonx will post -1.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pulmonx news, CEO Glendon E. French III sold 67,813 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $1.43, for a total value of $96,972.59. Following the transaction, the chief executive officer directly owned 1,409,511 shares of the company’s stock, valued at approximately $2,015,600.73. This trade represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 98,265 shares of company stock worth $140,519 in the last 90 days. Corporate insiders own 6.80% of the company’s stock.

Institutional Trading of Pulmonx

Several institutional investors and hedge funds have recently modified their holdings of LUNG. Corton Capital Inc. purchased a new stake in Pulmonx in the 2nd quarter valued at $32,000. Cerity Partners LLC bought a new stake in Pulmonx in the fourth quarter worth about $27,000. Opal Capital LLC purchased a new position in Pulmonx in the fourth quarter valued at approximately $29,000. Regatta Capital Group LLC purchased a new position in shares of Pulmonx during the 4th quarter valued at $30,000. Finally, Lazard Asset Management LLC purchased a new stake in Pulmonx during the fourth quarter valued at about $31,000. 91.04% of the stock is owned by hedge funds and other institutional investors.

Pulmonx News Summary

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx closed a five‑year senior secured credit facility for up to $60M (initial $40M drawn to refinance existing debt, $20M available subject to revenue milestones), extending debt maturities to 2031 and improving near‑term liquidity. Credit Facility Release
• Positive Sentiment: Q4 2025 results beat expectations: EPS loss of $0.25 vs. consensus -$0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year‑over‑year — evidence management is stabilizing operations. Earnings Release
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating and kept a $14 price target, which can attract momentum buyers given the large upside versus current levels. Analyst Note
• Neutral Sentiment: Profitability levers look better: Q4 gross margin improved to ~78% and operating expenses declined ~11%, but sustained recovery depends on revenue re‑acceleration. Financial Results
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below street consensus (~$94.1M), which caps near‑term upside and signals slower top‑line momentum. Guidance
• Negative Sentiment: Multiple insiders (including the CEO and general counsel) sold shares on March 2 — several Form 4 filings increase perceived selling pressure and may weigh on sentiment. SEC Filing
• Negative Sentiment: The new facility is relatively expensive (SOFR + 7.0% with a 3.75% floor and 2% PIK option) and includes warrants — it improves runway but raises interest costs and potential dilution. Financing Details

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.